FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324019831> ?p ?o ?g. }

• W4324019831 endingPage "10562" @default.
• W4324019831 startingPage "10553" @default.
• W4324019831 abstract "Abstract Background Approximately 40% patients of diffuse large B‐cell lymphoma (DLBCL) would develop disease recurrence/progression after first‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis. An effective strategy to prolong the survival of this patient population is the additional single‐drug maintenance therapy. lenalidomide, an immunomodulatory drug with oral activity, has direct anti‐tumor activity and indirect effects mediated by multiple immune cells in the tumor microenvironment, such as B, T, natural killer (NK), and dendritic cells. Combining its controllable toxicity, it is promising in long‐term maintenance therapy. This study aims at evaluating the clinical effect of lenalidomide maintenance therapy in responding DLBCL patients with R‐CHOP treatment. Methods This retrospective study was devised in DLBCL cases who obtained complete response (CR) or partial response (PR) following 6–8 cycles of R‐CHOP treatment between January 1, 2015 and July 31, 2019. Patients ( n = 141) included were respectively assigned to receive lenalidomide maintenance treatment (lenalidomide, n = 50) and drug‐free maintenance treatment (control, n = 91) after CR/PR. lenalidomide was provided orally at 25 mg/day for 10 days, with a cycle of 21 days and a treatment course of 2 years. Progression‐free survival (PFS) was taken as the primary outcome. Results Of the total 141 subjects, the median follow‐up time was 30.9 months (range, 5.7–68.9 months). The 2‐year PFS was 84% (95% CI: 74%–94%) in the lenalidomide group and 53% (95% CI: 43%–63%) in the control group. The median PFS of the lenalidomide group was not reached, and that of the control group was 42.9 months (HR = 0.32; 95% CI: 0.16–0.63; p = 0.001). No remarkable difference in overall survival (OS) between the two groups was indicated (HR = 0.42; 95% CI: 0.16–1.12; p = 0.08). Central nervous system (CNS) recurrence happened in 5 patients (5.5%) of the control group, while none of the patients with lenalidomide had CNS recurrence. Additionally, neutropenia and cutaneous reactions were the most common Grade 1–2 adverse reactions after lenalidomide treatment, and neutropenia was the most frequent Grade 3–4 adverse reaction. Conclusion Two‐year lenalidomide maintenance treatment can significantly prolong the PFS of DLBCL patients who obtained CR/PR to first‐line R‐CHOP treatment." @default.
• W4324019831 created "2023-03-14" @default.
• W4324019831 creator A5000057795 @default.
• W4324019831 creator A5004661714 @default.
• W4324019831 creator A5035064408 @default.
• W4324019831 creator A5088239929 @default.
• W4324019831 date "2023-03-13" @default.
• W4324019831 modified "2023-10-18" @default.
• W4324019831 title "<scp>Real‐world</scp> data for lenalidomide maintenance in responding patients of diffuse large <scp>B‐cell</scp> lymphoma" @default.
• W4324019831 cites W1799746163 @default.
• W4324019831 cites W1970400561 @default.
• W4324019831 cites W1994719395 @default.
• W4324019831 cites W2037688716 @default.
• W4324019831 cites W2047351266 @default.
• W4324019831 cites W2047395808 @default.
• W4324019831 cites W2066713758 @default.
• W4324019831 cites W2077848703 @default.
• W4324019831 cites W2100090512 @default.
• W4324019831 cites W2102602525 @default.
• W4324019831 cites W2110372244 @default.
• W4324019831 cites W2119147717 @default.
• W4324019831 cites W2126779872 @default.
• W4324019831 cites W2135860817 @default.
• W4324019831 cites W2136060045 @default.
• W4324019831 cites W2139836848 @default.
• W4324019831 cites W2145785161 @default.
• W4324019831 cites W2150587745 @default.
• W4324019831 cites W2153558008 @default.
• W4324019831 cites W2153665789 @default.
• W4324019831 cites W2166900358 @default.
• W4324019831 cites W2167556523 @default.
• W4324019831 cites W2171356556 @default.
• W4324019831 cites W2404692795 @default.
• W4324019831 cites W2471870867 @default.
• W4324019831 cites W2564026979 @default.
• W4324019831 cites W2566839935 @default.
• W4324019831 cites W2586396530 @default.
• W4324019831 cites W2588578827 @default.
• W4324019831 cites W2597924550 @default.
• W4324019831 cites W2598700764 @default.
• W4324019831 cites W2599557963 @default.
• W4324019831 cites W2605009867 @default.
• W4324019831 cites W2605767476 @default.
• W4324019831 cites W2615512219 @default.
• W4324019831 cites W2807205254 @default.
• W4324019831 cites W2810840907 @default.
• W4324019831 cites W2843787264 @default.
• W4324019831 cites W2889297222 @default.
• W4324019831 cites W2914256533 @default.
• W4324019831 cites W2989640927 @default.
• W4324019831 cites W3192574029 @default.
• W4324019831 cites W4324019831 @default.
• W4324019831 doi "https://doi.org/10.1002/cam4.5790" @default.
• W4324019831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36912128" @default.
• W4324019831 hasPublicationYear "2023" @default.
• W4324019831 type Work @default.
• W4324019831 citedByCount "1" @default.
• W4324019831 countsByYear W43240198312023 @default.
• W4324019831 crossrefType "journal-article" @default.
• W4324019831 hasAuthorship W4324019831A5000057795 @default.
• W4324019831 hasAuthorship W4324019831A5004661714 @default.
• W4324019831 hasAuthorship W4324019831A5035064408 @default.
• W4324019831 hasAuthorship W4324019831A5088239929 @default.
• W4324019831 hasBestOaLocation W43240198311 @default.
• W4324019831 hasConcept C126322002 @default.
• W4324019831 hasConcept C141071460 @default.
• W4324019831 hasConcept C143998085 @default.
• W4324019831 hasConcept C2776063141 @default.
• W4324019831 hasConcept C2776364478 @default.
• W4324019831 hasConcept C2776694085 @default.
• W4324019831 hasConcept C2776755627 @default.
• W4324019831 hasConcept C2778283404 @default.
• W4324019831 hasConcept C2778559949 @default.
• W4324019831 hasConcept C2779338263 @default.
• W4324019831 hasConcept C2779429289 @default.
• W4324019831 hasConcept C2779725641 @default.
• W4324019831 hasConcept C2780653079 @default.
• W4324019831 hasConcept C2908647359 @default.
• W4324019831 hasConcept C71924100 @default.
• W4324019831 hasConcept C90924648 @default.
• W4324019831 hasConcept C99454951 @default.
• W4324019831 hasConceptScore W4324019831C126322002 @default.
• W4324019831 hasConceptScore W4324019831C141071460 @default.
• W4324019831 hasConceptScore W4324019831C143998085 @default.
• W4324019831 hasConceptScore W4324019831C2776063141 @default.
• W4324019831 hasConceptScore W4324019831C2776364478 @default.
• W4324019831 hasConceptScore W4324019831C2776694085 @default.
• W4324019831 hasConceptScore W4324019831C2776755627 @default.
• W4324019831 hasConceptScore W4324019831C2778283404 @default.
• W4324019831 hasConceptScore W4324019831C2778559949 @default.
• W4324019831 hasConceptScore W4324019831C2779338263 @default.
• W4324019831 hasConceptScore W4324019831C2779429289 @default.
• W4324019831 hasConceptScore W4324019831C2779725641 @default.
• W4324019831 hasConceptScore W4324019831C2780653079 @default.
• W4324019831 hasConceptScore W4324019831C2908647359 @default.
• W4324019831 hasConceptScore W4324019831C71924100 @default.
• W4324019831 hasConceptScore W4324019831C90924648 @default.
• W4324019831 hasConceptScore W4324019831C99454951 @default.

• next